FOXP1 status in splenic marginal zone lymphoma: A fluorescence in situ hybridization and immunohistochemistry approach

Cristina Baró; Blanca Espinet; Marta Salido; Lluís Colomo; Elisa Luño; Lourdes Florensa; Ana Ferrer; Antonio Salar; Elias Campo; Sergi Serrano; Francesc Solé

FOXP1 status in splenic marginal zone lymphoma: A fluorescence in situ hybridization and immunohistochemistry approach

Cristina Baró, Blanca Espinet, Marta Salido, Lluís Colomo, Elisa Luño, Lourdes Florensa, Ana Ferrer, Antonio Salar, Elias Campo, Sergi Serrano, Francesc Solé

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

Splenic marginal zone lymphoma (SMZL) is a well-recognized entity in which chromosomal aberrations seem to be potential markers in diagnosis, prognosis and disease monitoring. FOXP1 is a transcriptional regulator of B lymphopoiesis that is deregulated in some types of NHL. Translocation t(3;14)(p14;q32) has been described in marginal zone lymphomas but few series have studied FOXP1 involvement in SMZL. We performed cytogenetic, fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) studies in a series of 36 patients in order to study the status of FOXP1 in this entity. According to our results, FOXP1 is not rearranged in SMZL, although we were able to demonstrate gains of FOXP1 gene due to trisomy 3/3p by FISH. FOXP1 protein expression seemed to be not related to any aberration and IHC studies are not conclusive.

Original language	English
Pages (from-to)	1399-1404
Journal	Histology and Histopathology
Volume	24
Issue number	11
Publication status	Published - 1 Nov 2009

Keywords

FISH
FOXP1
IHC
SMZL

Cite this

@article{376f81c7cce74a8c8cd5c6026c2e46d0,

title = "FOXP1 status in splenic marginal zone lymphoma: A fluorescence in situ hybridization and immunohistochemistry approach",

abstract = "Splenic marginal zone lymphoma (SMZL) is a well-recognized entity in which chromosomal aberrations seem to be potential markers in diagnosis, prognosis and disease monitoring. FOXP1 is a transcriptional regulator of B lymphopoiesis that is deregulated in some types of NHL. Translocation t(3;14)(p14;q32) has been described in marginal zone lymphomas but few series have studied FOXP1 involvement in SMZL. We performed cytogenetic, fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) studies in a series of 36 patients in order to study the status of FOXP1 in this entity. According to our results, FOXP1 is not rearranged in SMZL, although we were able to demonstrate gains of FOXP1 gene due to trisomy 3/3p by FISH. FOXP1 protein expression seemed to be not related to any aberration and IHC studies are not conclusive.",

keywords = "FISH, FOXP1, IHC, SMZL",

author = "Cristina Bar{\'o} and Blanca Espinet and Marta Salido and Llu{\'i}s Colomo and Elisa Lu{\~n}o and Lourdes Florensa and Ana Ferrer and Antonio Salar and Elias Campo and Sergi Serrano and Francesc Sol{\'e}",

year = "2009",

month = nov,

day = "1",

language = "English",

volume = "24",

pages = "1399--1404",

journal = "Histology and Histopathology",

issn = "0213-3911",

publisher = "Histology and Histopathology",

number = "11",

}

TY - JOUR

T1 - FOXP1 status in splenic marginal zone lymphoma: A fluorescence in situ hybridization and immunohistochemistry approach

AU - Baró, Cristina

AU - Espinet, Blanca

AU - Salido, Marta

AU - Colomo, Lluís

AU - Luño, Elisa

AU - Florensa, Lourdes

AU - Ferrer, Ana

AU - Salar, Antonio

AU - Campo, Elias

AU - Serrano, Sergi

AU - Solé, Francesc

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Splenic marginal zone lymphoma (SMZL) is a well-recognized entity in which chromosomal aberrations seem to be potential markers in diagnosis, prognosis and disease monitoring. FOXP1 is a transcriptional regulator of B lymphopoiesis that is deregulated in some types of NHL. Translocation t(3;14)(p14;q32) has been described in marginal zone lymphomas but few series have studied FOXP1 involvement in SMZL. We performed cytogenetic, fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) studies in a series of 36 patients in order to study the status of FOXP1 in this entity. According to our results, FOXP1 is not rearranged in SMZL, although we were able to demonstrate gains of FOXP1 gene due to trisomy 3/3p by FISH. FOXP1 protein expression seemed to be not related to any aberration and IHC studies are not conclusive.

AB - Splenic marginal zone lymphoma (SMZL) is a well-recognized entity in which chromosomal aberrations seem to be potential markers in diagnosis, prognosis and disease monitoring. FOXP1 is a transcriptional regulator of B lymphopoiesis that is deregulated in some types of NHL. Translocation t(3;14)(p14;q32) has been described in marginal zone lymphomas but few series have studied FOXP1 involvement in SMZL. We performed cytogenetic, fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) studies in a series of 36 patients in order to study the status of FOXP1 in this entity. According to our results, FOXP1 is not rearranged in SMZL, although we were able to demonstrate gains of FOXP1 gene due to trisomy 3/3p by FISH. FOXP1 protein expression seemed to be not related to any aberration and IHC studies are not conclusive.

KW - FISH

KW - FOXP1

KW - IHC

KW - SMZL

M3 - Article

SN - 0213-3911

VL - 24

SP - 1399

EP - 1404

JO - Histology and Histopathology

JF - Histology and Histopathology

IS - 11

ER -

FOXP1 status in splenic marginal zone lymphoma: A fluorescence in situ hybridization and immunohistochemistry approach

Abstract

Keywords

Fingerprint

Cite this